Assessing the Pathophysiology of Hyperglycemia in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium. Issue 6 (July 2022)

• Record Type: Journal Article
• Authors: Dungan, Kathleen M.; Hart, Phil A.; Andersen, Dana K.; Basina, Marina; Chinchilli, Vernon M.; Danielson, Kirstie K.; Evans-Molina, Carmella; Goodarzi, Mark O.; Greenbaum, Carla J.; Kalyani, Rita R.; Laughlin, Maren R.; Pichardo-Lowden, Ariana; Pratley, Richard E.; Serrano, Jose; Sims, Emily K.; Speake, Cate; Yadav, Dhiraj; Bellin, Melena D.; Toledo, Frederico G. S.
• Is Part Of: Pancreas. Volume 51:Issue 6(2022)
• Page Start: 575
• Page End: 579
• Publication Date: 2022-07
• Subjects: type 3c diabetes mellitus -- β-cell function -- frequently sampled intravenous glucose tolerance test -- mixed-meal tolerance test -- islet -- pancreatogenic diabetes -- AIRg - acute insulin response to glucose -- AP - acute pancreatitis -- AUC - area under the curve -- DM - diabetes mellitus -- DREAM - Diabetes Related to Acute Pancreatitis and its Mechanisms -- FSIGTT - frequently sampled intravenous glucose tolerance test -- GIP - glucose-dependent insulinotropic polypeptide -- GLP-1 - glucagon-like peptide 1 -- HOMA-IR - homeostasis model assessment–insulin resistance -- OGTT - oral glucose tolerance test -- MMTT - mixed meal tolerance test -- PP - pancreatic polypeptide; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000002074
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objectives: The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods: Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions: The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.